These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31910684)

  • 1. Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
    Irwin DE; Wilson K; Hoehn G; Min S; Szabo E
    Curr Med Res Opin; 2020 Mar; 36(3):439-444. PubMed ID: 31910684
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
    Irwin D; Wilson K; Thompson S; Choudhry A
    Curr Med Res Opin; 2021 Apr; 37(4):623-628. PubMed ID: 33563073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
    Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
    Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Rummel MJ; Janssens A; MacDonald D; Keating MM; Zaucha JM; Davis J; Lasher J; Babanrao Pisal C; Izquierdo M; Friedberg JW
    Br J Haematol; 2021 Jun; 193(6):1123-1133. PubMed ID: 33973233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
    Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
    Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
    Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
    Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
    Sancho JM; Abrisqueta P; Kumar A; Cordoba R; Tani M; Langmuir P; Rappold E; Liu T; Lopez-Guillermo A
    Leuk Lymphoma; 2024 Jul; 65(7):911-921. PubMed ID: 38598516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
    Lyons RM; Shtivelband M; Kingsley E; Moezi M; Richards D; Sharman J; Feng X; Cannan M; Fellague-Chebra R; Boyd TE
    Leuk Lymphoma; 2021 Jun; 62(6):1353-1360. PubMed ID: 33448893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
    Lavezzi SM; de Jong J; Neyens M; Cramer P; Demirkan F; Fraser G; Bartlett N; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Goy A; Ganguly S; Salman M; Howes A; Mahler M; De Nicolao G; Poggesi I
    Pharm Res; 2019 May; 36(7):93. PubMed ID: 31044267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Ribes D; Hachem HEL; Oberic L; Vergez F; Delas A; Belliere J; Protin C; Kamar N; Ferrandiz I; Tavitian S; Laurent C; Huart A; Chauveau D; Ysebaert L; Faguer S
    Am J Hematol; 2018 Mar; 93(3):356-362. PubMed ID: 29168251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.